BNP Paribas Asset Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.3M | Sell |
44,851
-27,864
| -38% | -$15.7M | 0.02% | 536 |
|
|
2026
Q1 | $43.1M | Buy |
72,715
+8,178
| +13% | +$4.07M | 0.05% | 356 |
|
|
2025
Q4 | $31.5M | Buy |
+64,537
| New | +$30.1M | 0.04% | 427 |
|
|
2025
Q3 | – | Sell |
-91,117
| Closed | -$26.2M | – | 2076 |
|
|
2025
Q2 | $26.2M | Buy |
91,117
+30,487
| +50% | +$9.11M | 0.06% | 289 |
|
|
2025
Q1 | $18.7M | Buy |
60,630
+2,854
| +5% | +$978K | 0.05% | 355 |
|
|
2024
Q4 | $20.4M | Buy |
57,776
+25,684
| +80% | +$9.44M | 0.05% | 339 |
|
|
2024
Q3 | $11.5M | Buy |
32,092
+12,566
| +64% | +$4.24M | 0.03% | 414 |
|
|
2024
Q2 | $6.22M | Buy |
+19,526
| New | +$5.17M | 0.02% | 493 |
|
|
2023
Q3 | – | Sell |
-1,998
| Closed | -$441K | – | 864 |
|
|
2023
Q2 | $441K | Buy |
1,998
+1,069
| +115% | +$237K | ﹤0.01% | 788 |
|
|
2023
Q1 | $208K | Buy |
+929
| New | +$229K | ﹤0.01% | 868 |
|
|
2022
Q3 | – | Sell |
-25,800
| Closed | -$6.08M | – | 971 |
|
|
2022
Q2 | $6.08M | Buy |
+25,800
| New | +$5.25M | 0.02% | 494 |
|
|
2019
Q2 | – | Sell |
-6,733
| Closed | -$790K | – | 957 |
|
|
2019
Q1 | $790K | Buy |
6,733
+61
| +0.9% | +$7.11K | 0.01% | 734 |
|
|
2018
Q4 | $701K | Buy |
6,672
+377
| +6% | +$43.7K | 0.01% | 753 |
|
|
2018
Q3 | $805K | Sell |
6,295
-5,848
| -48% | -$723K | 0.01% | 734 |
|
|
2018
Q2 | $1.37M | Sell |
12,143
-7,394
| -38% | -$813K | 0.01% | 688 |
|
|
2018
Q1 | $2.19M | Buy |
19,537
+11,269
| +136% | +$1.43M | 0.02% | 618 |
|
|
2017
Q4 | $1.22M | Buy |
8,268
+2,480
| +43% | +$315K | 0.01% | 707 |
|
|
2017
Q3 | $678K | Buy |
+5,788
| New | +$739K | 0.01% | 793 |
|
|
2017
Q2 | – | Sell |
-5,314
| Closed | -$719K | – | 977 |
|
|
2017
Q1 | $719K | Sell |
5,314
-3,597
| -40% | -$545K | 0.01% | 801 |
|
|
2016
Q4 | $1.28M | Sell |
8,911
-2,570
| -22% | -$328K | 0.01% | 733 |
|
|
2016
Q3 | $1.36M | Buy |
11,481
+9,250
| +415% | +$1.11M | 0.01% | 777 |
|
|
2016
Q2 | $236K | Sell |
2,231
-13,041
| -85% | -$1.45M | ﹤0.01% | 1062 |
|
|
2016
Q1 | $1.7M | Sell |
15,272
-9,733
| -39% | -$1.23M | 0.01% | 714 |
|
|
2015
Q4 | $3.92M | Buy |
25,005
+935
| +4% | +$136K | 0.03% | 525 |
|
|
2015
Q3 | $3.16M | Sell |
24,070
-246
| -1% | -$39.5K | 0.03% | 573 |
|
|
2015
Q2 | $4.23M | Buy |
24,316
+22,123
| +1,009% | +$3.98M | 0.03% | 540 |
|
|
2015
Q1 | $378K | Buy |
+2,193
| New | +$334K | ﹤0.01% | 950 |
|
Other funds holding UTHR
ACA
JT
BNP Paribas Asset Management's UTHR Position: Q2 2026 in Review
BNP Paribas Asset Management reduced its United Therapeutics (UTHR) stake by 38% in Q2 2026, selling an estimated $15.7M and leaving 44,851 shares worth $24.3M. The position accounts for 0.02% of the portfolio, ranked #536.
BNP Paribas Asset Management first reported a position in UTHR in Q1 2015 and has held it in 27 quarters since. The position peaked at $43.1M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- BNP Paribas Asset Management held 44,851 shares of United Therapeutics worth $24.3M as of Q2 2026.
- BNP Paribas Asset Management sold 27,864 United Therapeutics shares in Q2 2026, an estimated $15.7M.
- United Therapeutics made up 0.02% of BNP Paribas Asset Management's portfolio in Q2 2026, its #536 holding.
- BNP Paribas Asset Management first reported a position in United Therapeutics in Q1 2015 and has held it in 27 quarters since.
- BNP Paribas Asset Management's United Therapeutics position peaked at $43.1M in Q1 2026.
- 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.